ROCKVILLE, Md., Jan. 24, 2022 /PRNewswire/ — Today, the Heart Failure Society of America (HFSA) released a review, Economic Issues in Heart Failure in the United States, in the Journal of Cardiac Failure (JCF). The review examines the growing economic burden of heart failure for patients and the health care system in the United States, providing a summary of […]
Author: Ken Dropiewski
Peerbridge Health and Northwell Health Launch Pilot Program to Optimize Treatment for AFib Patients at Lenox Hill Hospital
NEW YORK, Jan. 25, 2022 /PRNewswire/ — Peerbridge Health is collaborating with Northwell Health on their newly launched AFib Center of Excellence, a mutli-displinary effort that optimizes treatment for patients with atrial fibrillation (AFib). With Peerbridge’s support, Northwell’s AFib Center of Excellence will conduct a pilot program focusing on AFib patients with undiagnosed […]
Johnson & Johnson Reports Q4 and Full-Year 2021 Results
– 2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6%*, and adjusted operational sales growth of 12.3%* – 2021 Full-Year Sales of $93.8 Billion reflecting growth of 13.6%, operational sales growth of 12.2%*, and adjusted operational sales growth of 12.8%* – 2021 Fourth-Quarter EPS […]
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
Expanding patient base and potential of Imara’s small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched PDE9 expression for targeted approach to a heterogeneous disease Study initiation planned for second quarter of 2022 BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) […]
Impulse Dynamics Announces Chief Financial Officer Transition
Harriss Currie to Succeed Gerry Haines MARLTON, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure, today announced the appointment of Harriss T. Currie as Executive Vice President and Chief Financial Officer. Currie succeeds Gerald M. Haines […]
HonorHealth Scottsdale Shea Medical Center Builds Advanced Robotic Program to Treat Heart Rhythm Disorders
ST. LOUIS, Jan. 25, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that HonorHealth has established a robotic electrophysiology program as part of its Cardiovascular Center of Excellence at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona. HonorHealth is […]
Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk
Post hoc analysis of the CHAMPION PHOENIX clinical trial demonstrates that the majority of ischemic events occurred early in percutaneous coronary intervention (PCI), and KENGREAL® (cangrelor) treatment significantly reduced these events in the first two hours post-randomization compared to clopidogrel (4.1% vs 5.4%, p=0.002) CARY, N.C., Jan. 25, 2022 (GLOBE […]
Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of EnACT (all oral induction regimen) Underway With Six Patients Enrolled and Topline Interim Data […]
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022. AtriCure will host a […]
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
WILMINGTON, Del., January 24, 2022 – Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition. Eplontersen, formerly known as IONIS-TTR-LRx, is a ligand-conjugated antisense (LICA) investigational medicine currently in […]



